Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Patheon has completed a shareholders agreement and a sales and marketing agreement with BSP Pharmaceuticals, a company focused on the development and manufacturing of cytotoxic pharmaceutical products.
Subscribe to our email newsletter
Under the terms of the sales and marketing agreement, Patheon will promote BSP’s cytotoxic manufacturing capacity and development services. Aldo Braca, president of Patheon Europe will be president and CEO of BSP Pharmaceuticals.
Patheon is in the process of identifying a successor to Mr Braca and for a transitional period, Mr Braca will fill both roles.
Wes Wheeler, president and CEO of Patheon, said: “With these agreements in place, Patheon can now offer its clients a complete suite of services – which now includes cytotoxics – in contract manufacturing and formulation development.”